|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||
| The monoclonal antibody 50 recognizes human MALT1 (Mucosal Associated Lymphoid Tissue lymphoma translocation gene 1). MALT1 is a 91 kDa paracaspase that contains a death domain, two Ig-like domains and a C terminal caspase-like domain. Like other caspases, it cleaves substrates after an arginine residue. Expression is found in the cytoplasm of B and T cells. Within B cell follicles, MALT1 expression is highly expressed in centroblasts, followed by centrocytes and weakly expressed in the mantle zone. The interaction of MALT1 and Bcl10 occurs through Ig-like domains resulting in oligomerization and activation of the caspase-like domain. This also directly results in NFκ B activation thereby playing a role in B cell maturation and activation. Rearrangements of the MALT1 gene found in t(11;18)(q21;q21) and t(14;18)(q32;q21) are the most frequent structural chromosomal abnormalities in MALT lymphomas. These translocations lead to fusions of API2(BIRC3)–MALT1 and IGH–MALT1 respectively. An additional translocation between MALT1 and MAP4 has also been identified in DLBCL (diffuse large B- cell lymphoma). The antibody 50 reacts with the C terminal domain of MALT1, which allows for the detection of endogenous MALT1 as well as both identified fusion proteins resulting from translocation events. | ||||||||||||||||||||||||
| Applications Reported | ||||||||||||||||||||||||
| For research use only, not for diagnostic or therapeutic use. This 50 antibody has been reported for use in immunoblotting (WB) and immunohistochemical staining of formalin-fixed, paraffin embedded tissue sections. | ||||||||||||||||||||||||
| Applications Tested | ||||||||||||||||||||||||
| This 50 antibody has been tested by immunohistochemistry on formalin-fixed paraffin-embedded (FFPE) human tonsil tissue. Antigen retrieval was performed using 10mM citrate buffer at pH 6.0. For immunohistochemistry, this antibody can be used at less than or equal to 10 μg/mL. This 50 antibody has been tested by western blotting under reducing conditions (at 5 μg/ml) on Jurkat cells. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. | ||||||||||||||||||||||||
| References | ||||||||||||||||||||||||
| Murga Penas EM, Kawadler H, Siebert R, Frank M, Ye H, Hinz K, Becher C, Hummel M, Barth TF, Bokemeyer C, Stein H, Trümper L, Möller P, Marynen P, Du MQ, Yang X, Hansmann ML, Dierlamm J. A novel fusion of the MALT1 gene and the microtubule-associated protein 4 (MAP4) gene occurs in diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2006 Sep;45(9):863-73 (50, IHC paraffin, PubMed) Nakagawa M, Hosokawa Y, Yonezumi M, Izumiyama K, Suzuki R, Tsuzuki S, Asaka M, Seto M. MALT1 contains nuclear export signals and regulates cytoplasmic localization of BCL10. Blood. 2005 Dec 15;106(13):4210-6. Ye H, Gong L, Liu H, Hamoudi RA, Shirali S, Ho L, Chott A, Streubel B, Siebert R, Gesk S, Martin-Subero JI, Radford JA, Banerjee S, Nicholson AG, Ranaldi R, Remstein ED, Gao Z, Zheng J, Isaacson PG, Dogan A, Du MQ. MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. J Pathol. 2005 Feb;205(3):293-301. (50, WB, IHC paraffin, PubMed) | ||||||||||||||||||||||||
| Home | Index | Site Map | FAQ | Terms & Conditions | Distributors | Careers | Contact Us |
|
Copyright © 2000-2010 eBioscience, Inc. Unless indicated otherwise, all products are For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for further distribution without written consent. Not all products available in all regions. |